Crystal structure of visfatin/ pre B-cell colony–enhancing factor1/nicotinamide phosphoribosyltransferase, free and in complex with the anti cancer agent FK-866

Author(s): Kim MK, Lee JH, Kim H, Park SJ, Kim SH, et al.

Abstract

Visfatin/pre-B cell colony-enhancing factor 1 (PBEF)/nicotinamide phosphoribosyltransferase (NAmPRTase) is a multifunctional protein having phosphoribosyltransferase, cytokine and adipokine activities. Originally isolated as a cytokine promoting the differentiation of B cell precursors, it was recently suggested to act as an insulin analog via the insulin receptor. Here, we describe the first crystal structure of visfatin in three different forms: apo and in complex with either nicotinamide mononucleotide (NMN) or the NAmPRTase inhibitor FK-866 which was developed as an anti-cancer agent, interferes with NAD biosynthesis, showing a particularly high specificity for NAmPRTase. The crystal structures of the complexes with either NMN or FK-866 show that the enzymatic active site of visfatin is optimized for nicotinamide binding and that the nicotinamide-binding site is important for inhibition by FK-866. Interestingly, visfatin mimics insulin signaling by binding to the insulin receptor with an affinity similar to that of insulin and does not share the binding site with insulin on the insulin receptor. To predict binding sites, the potential interaction patches of visfatin and the L1-CR-L2 domain of insulin receptor were generated and analyzed. Although the relationship between the insulin-mimetic property and the enzymatic function of visfatin has not been clearly established, our structures raise the intriguing possibility that the glucose metabolism and the NAD biosynthesis are linked by visfatin.

Similar Articles

Visfatin/PBEF and Atherosclerosis-Related Diseases

Author(s): Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP

Age of onset and type of diabetes

Author(s): Laakso M, Pyorala K

Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients

Author(s): Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, et al.

Leptin increase is associated with markers of the hemostatic system in obese healthy women

Author(s): Guagnano MT, Romano M, Falco A, Nutini M, Marinopiccoli M, et al.

Effect of exercise training on plasma visfatin and eotaxin levels

Author(s): Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, et al.

Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children

Author(s): Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, et al.

An evaluation of visfatin levels in obese subjects

Author(s): Kaminska A, Kopczynska E, Bronisz A, Zmudzinska M, Bielinski M, et al.

Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding

Author(s): Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, et al.

Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass

Author(s): García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, et al.

The visfatin gene is associated with glucose and lipid metabolism in a Chinese population

Author(s): Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S et al.

Serum visfatin increases with progressive beta-cell deterioration

Author(s): López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, et al.

Adipose tissue as an endocrine organ

Author(s): Kershaw EE, Flier JS

Obesity, hypertension and insulin resistance

Author(s): Sharma AM, Chetty VT

Regulation of adipocytokines and insulin resistance

Author(s): Fasshauer M, Paschke R